{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:25:51Z","timestamp":1783416351574,"version":"3.54.6"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"\u00c4\u00b0lko Pharmaceuticals"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,22]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Levodopa combined with carbidopa and entacapone (LCE) and levodopa combined with benserazide (LB) are commonly used treatment options in every stage of Parkinson\u2019s disease. Although both combinations aim to enhance dopamine bioavailability and improve motor symptoms, their short-term biochemical effects remain to be clarified. This study aims to compare the short-term effects of LCE and LB on plasma dopamine levels in patients with early-stage, unilateral Parkinson\u2019s disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This prospective, single-center, randomized controlled study included patients diagnosed with early-stage Parkinson\u2019s disease presenting with unilateral motor symptoms. Participants were randomly assigned to receive either LCE or LB therapy. This study was a randomized controlled trial performed according to the Consolidated Standards of Reporting Trials (CONSORT). Venous blood samples were collected before drug administration and at 90- and 180-minute post-administration to measure plasma dopamine levels using high-performance liquid chromatography.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Ninety patients were included in the study. Of these, 34.4% were female, and the median age was 69.5 years. The tremor-dominant subtype was observed in 92.2% of patients. LCE was administered to 48.9% of the patients, while 51.1% received LB. Both LCE and LB led to increases in plasma dopamine concentrations within the first 180 minutes. However, no significant difference was observed between the 2 treatment groups and within groups over time, in terms of dopamine elevation (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&gt;\u2005.05, all values).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this study, no significant difference was observed in the short-term effects of LCE and LB combinations on plasma dopamine levels in patients with early-stage Parkinson\u2019s disease with unilateral involvement. Further large-scale, multicenter studies with extended follow-up are required to assess long-term clinical outcomes, including motor response duration and adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048895","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T17:00:09Z","timestamp":1779469209000},"page":"e48895","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of blood dopamine in Parkinson\u2019s patients treated with levodopa carbidopa entacapone vs levodopa benserazide: A randomized controlled trial"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6354-3297","authenticated-orcid":false,"given":"Osman","family":"Korucu","sequence":"first","affiliation":[{"name":"Department of Neurology, Atat\u00fcrk Sanatoryum Training and Research Hospital, Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5294-9061","authenticated-orcid":false,"given":"Sedat","family":"\u00d6zdemir","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry, Atat\u00fcrk Sanatoryum Training and Research Hospital, Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4494-6378","authenticated-orcid":false,"given":"G\u00fcls\u00fcm Feyza","family":"T\u00fcrke\u015f","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Ankara University Medicine Faculty, Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4766-1941","authenticated-orcid":false,"given":"Volkan","family":"Savici","sequence":"additional","affiliation":[{"name":"Department of Neurology, Atat\u00fcrk Sanatoryum Training and Research Hospital, Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6056-4401","authenticated-orcid":false,"given":"Emine","family":"Emektar","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Atat\u00fcrk Sanatoryum Training and Research Hospital, Ankara, T\u00fcrkiye."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260707","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2174\/1871527318666190314101314","article-title":"Safety and efficacy of levetiracetam for the management of levodopa-induced dyskinesia in patients with Parkinson\u2019s disease: a systematic review.","volume":"18","author":"Ebada","year":"2019","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"R2-20260707","doi-asserted-by":"crossref","first-page":"e000573","DOI":"10.1136\/bmjno-2023-000573","article-title":"Efficacy and safety of adjunctive oral therapy in Parkinson\u2019s disease with motor complications: a systematic review and network meta-analysis.","volume":"6","author":"Sisodia","year":"2024","journal-title":"BMJ Neurol Open"},{"key":"R3-20260707","doi-asserted-by":"crossref","first-page":"e2408","DOI":"10.1002\/brb3.2408","article-title":"Polyneuropathy monitoring in Parkinson\u2019s disease patients treated with levodopa\/carbidopa intestinal gel.","volume":"11","author":"Pauls","year":"2021","journal-title":"Brain Behav"},{"key":"R4-20260707","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMra2401857","article-title":"Parkinson\u2019s disease.","volume":"391","author":"Tanner","year":"2024","journal-title":"N Engl J Med"},{"key":"R5-20260707","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(23)01429-0","article-title":"Medical, surgical, and physical treatments for Parkinson\u2019s disease.","volume":"403","author":"Foltynie","year":"2024","journal-title":"Lancet"},{"key":"R6-20260707","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s13318-021-00683-3","article-title":"Investigating the impact of gastric emptying on pharmacokinetic parameters using delay differential equations and principal component analysis.","volume":"46","author":"Karatza","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R7-20260707","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12883-025-04128-1","article-title":"The efficacy of levodopa\/carbidopa\/entacapone on cognitive function in moderate to advanced Parkinson\u2019s disease and its relationship with peripheral inflammatory cytokines.","volume":"25","author":"Xu","year":"2025","journal-title":"BMC Neurol"},{"key":"R8-20260707","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40120-024-00629-2","article-title":"The Catechol O-methyltransferase inhibitor entacapone in the treatment of Parkinson\u2019s disease: personal reflections on a first-in-class drug development programme 40 years on.","volume":"13","author":"M\u00e4nnist\u00f6","year":"2024","journal-title":"Neurol Ther"},{"key":"R9-20260707","doi-asserted-by":"crossref","first-page":"17562864221108018","DOI":"10.1177\/17562864221108018","article-title":"Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson\u2019s disease: real-world experience and practical guidance.","volume":"15","author":"Nyholm","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"key":"R10-20260707","doi-asserted-by":"crossref","first-page":"e16535","DOI":"10.1111\/ene.16535","article-title":"Effectiveness and safety of levodopa-entacapone-carbidopa infusion in Parkinson disease: a real-world data study.","volume":"32","author":"Santos-Garc\u00eda","year":"2025","journal-title":"Eur J Neurol"},{"key":"R11-20260707","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/mdc3.14044","article-title":"Motor complications in Parkinson\u2019s disease: results from 3343 patients followed for up to 12 years.","volume":"11","author":"Gandhi","year":"2024","journal-title":"Mov Disord Clin Pract"},{"key":"R12-20260707","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40265-014-0343-0","article-title":"Catechol-O-methyltransferase inhibitors in Parkinson\u2019s disease.","volume":"75","author":"M\u00fcller","year":"2015","journal-title":"Drugs"},{"key":"R13-20260707","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00702-003-0004-z","article-title":"Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson\u2019s disease.","volume":"110","author":"Blandini","year":"2003","journal-title":"J Neural Transm (Vienna)"},{"key":"R14-20260707","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/mds.870120404","article-title":"Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson\u2019s disease.","volume":"12","author":"Lyytinen","year":"1997","journal-title":"Mov Disord"},{"key":"R15-20260707","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/phrs.2001.0819","article-title":"Monitoring of L-dopa concentrations in Parkinson\u2019s disease.","volume":"43","author":"Furlanut","year":"2001","journal-title":"Pharmacol Res"},{"key":"R16-20260707","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00702-015-1449-6","article-title":"Efficacy and safety of entacapone in levodopa\/carbidopa versus levodopa\/benserazide-treated Parkinson\u2019s disease patients wearing off.","volume":"122","author":"Kuoppam\u00e4ki","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"key":"R17-20260707","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00228-009-0622-y","article-title":"Comparison of the pharmacokinetic profile of levodopa throughout the day between levodopa\/carbidopa\/entacapone and levodopa\/carbidopa when administered four or five times daily.","volume":"65","author":"Kuoppam\u00e4ki","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"R18-20260707","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2147\/TCRM.S163190","article-title":"Levodopa\/carbidopa\/entacapone versus levodopa\/dopa-decarboxylase inhibitor for the treatment of Parkinson\u2019s disease: systematic review, meta-analysis, and economic evaluation.","volume":"14","author":"Yi","year":"2018","journal-title":"Ther Clin Risk Manag"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048895","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:00:11Z","timestamp":1783414811000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":18,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048895","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2025-06-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}